Acneiform Eruptions Clinical Trial
Official title:
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects With Neoplasm Receiving EGFRi or MEKi Therapy
Efficacy and Safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (EGFRi)/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor (MEKi)-associated acneiform Rash
This study is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of imsidolimab compared with placebo in cancer participants with EGFRi/MEKi-associated acneiform rash. This study will also characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in participants with EGFRi/MEKi-associated acneiform rash. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04864717 -
Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI
|
Phase 4 | |
Active, not recruiting |
NCT05120362 -
A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash
|
N/A | |
Active, not recruiting |
NCT05919810 -
The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne
|
N/A |